

Published in final edited form as:

Circ Cardiovasc Qual Outcomes. 2010 March ; 3(2): 111–115. doi:10.1161/CIRCOUTCOMES.109.925313.

Ischemic Heart Disease in Women: Many Questions, Few Facts

Viola Vaccarino, MD, PhD

Department of Medicine, Division of Cardiology, Emory University School of Medicine, and
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

After at least two decades of growing awareness on coronary heart disease in women, we are left with many questions, few answers, and plenty of opinions. Review papers, books, sessions at scientific meetings and commentaries regarding various aspects of heart disease in women have proliferated. These reports have highlighted important sex differences in the pathophysiology, presentation and treatment of ischemic heart disease, and have denounced pervasive sex-related disparities in referral and treatment for heart disease as a major reason for outcome differences between the sexes. Such activities have been useful in driving attention to heart disease in women, an area largely ignored by the scientific community and the public just 15–20 years ago. However, we must recognize that, to date, limited data substantiate many of these statements; such recognition is important to guide future research efforts. A careful look at recently published literature reveals only modest advancements towards clarifying sex-based differences in the pathophysiology of ischemic heart disease and sex-based differences in outcome. At the same time, key questions concerning strategies for prevention and treatment of heart disease in women remain unanswered, and cardiovascular clinical trials continue to include fewer women than men.¹

Is the Pathophysiology of Ischemic Heart Disease Different in Women than Men?

A fundamental question is whether the mechanisms underlying ischemic heart disease in women differ from those in men. This is an important question because, if pathophysiology differs in women, such differences can inform strategies for prevention, detection and treatment that would be most effective for women. That pathophysiology may differ in women compared with men is suggested by several factors. First, despite having more symptoms and physical limitations,^{2, 3} women have less obstructive coronary heart disease than men along the entire spectrum of acute coronary syndromes⁴ and when referred for revascularization.^{5, 6} Second, the syndrome of chest pain without obstructive coronary artery disease (CAD) is distinctly more common in women than in men.⁷ Third, among women, chest pain symptoms and disability do not correlate with severity of coronary stenoses.⁸ Fourth, women, particularly those who are young or middle-aged (whom one would expect to be most advantaged for coronary disease risk compared with men), show higher rates of adverse outcomes after acute myocardial infarction than men of similar age, despite less severe coronary narrowing, smaller infarcts, and more preserved systolic

Address for Correspondence: Viola Vaccarino, MD, PhD, Emory University School of Medicine, Department of Medicine, Division of Cardiology, 1256 Briarcliff Road NE, Bldg A, Suite-1 North, Atlanta, GA 30306, Phone: 404-712-9120, Fax: 404-727-6495, viola.vaccarino@emory.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest Disclosures: None.

function.⁹ To explain these observations, a number of abnormalities in coronary vascular structure and function have been proposed that could lead to symptoms, disability and other adverse outcomes in the absence of critical coronary stenosis.^{10–12} These include positive remodeling (compensatory vessel enlargement), diffuse atherosclerosis (vs plaque), coronary endothelial dysfunction leading to vasoconstriction, and microvascular disease. Coronary microvascular disease, in particular, is put forward as a major etiological factor for ischemic heart disease in women, and a prevalent determinant of chest pain, ischemia and disability in women (“microvascular angina”).¹² Consequently, the identification of nonobstructive atheroma has been put forth as a potentially helpful strategy for the risk stratification of women.¹²

Although this is a compelling theory, to date there is little evidence to suggest that vascular abnormalities in the absence of obstructive atheroma are more commonly implicated in the pathogenesis of ischemia among women than men. Recent studies have evaluated sex differences in coronary structure and function using intravascular ultrasound (IVUS) and other types of vascular testing. In a sample of 978 patients with established CAD, Nicholls et al. found no sex difference in arterial remodeling; in this study, women were as likely as men to undergo either positive or negative remodeling.¹³ In a study of 142 patients referred for coronary evaluation and found to be free of obstructive CAD, women did not show worse endothelial function than men.¹⁴ Women actually had less epicardial coronary endothelial dysfunction than men (shorter coronary artery segments affected), even after correction for body size. The few studies that have compared endothelium-independent vasodilatory reserve in response to adenosine (an index of microvascular function) have reported similar values in women and men referred for coronary angiography;^{14–15} in one study it was lower in women, but this difference was largely explained by the women’s older age and smaller body size.¹⁴ All IVUS studies have found that women had less atheroma volume than men, including both luminal plaque and atheroma within the media, despite older age and more risk factors, and even after accounting for body surface area and vessel size.^{13, 14, 16} Women also have smaller coronary vessels after adjusting for body size.¹⁶

Although these studies confirmed the known clinical observation that women with established or suspected CAD have lower plaque burden than men, they were unable to identify other vascular abnormalities that might explain sex differences in clinical presentation. If anything, women showed *better* endothelial function than men; this result parallels the known finding from community samples that women have better peripheral endothelial function than men (measured as flow-mediated vasodilation % from baseline) until about age 70 and at all levels of risk factors.^{17–19} Similarly, asymptomatic women compared with asymptomatic men have *higher* coronary perfusion reserve measured with magnetic resonance imaging, a measure of global coronary vasculature vasoreactivity,²⁰ although this difference is in part explained by differences in risk factors. This does not mean that coronary vascular dysfunction, when present, is not prognostically important in women; however even in this respect, data are limited. The Women’s Ischemia Syndrome Evaluation (WISE) study has provided substantial information on this topic. Unfortunately, many of these reports are limited by the characteristics of the sample selection, the small number of “hard” endpoints and the lack of a male comparison group. In a sample of 163 women enrolled in WISE, all referred for clinically indicated coronary angiography and assessed for coronary reactivity, those with impaired vasodilation to intracoronary acetylcholine had a higher rate of subsequent coronary events than those without.²¹ Unfortunately, in this small sample the results were driven by hospitalizations for angina and percutaneous interventions (36 out of 58 events). WISE investigators also studied 35 women who were hospitalized for chest pain but who had no angiographically significant coronary artery obstructions, and compared them with 12 age- and weight-matched control

women with no evidence of heart disease. Phosphorus-31 nuclear magnetic resonance (³¹P-NMR) spectroscopy was done before and after isometric handgrip exercise. Seven (20 percent) of the 35 women with chest pain and no angiographically significant stenosis had decreases in the phosphocreatine:ATP ratio (a metabolic marker of ischemia) during exercise that were more than 2 SD below the mean value in the control subjects without chest pain, suggesting that a subgroup of women presenting with chest pain and normal angiograms may have ischemia due to microvascular coronary disease.²² A follow-up of these women within the WISE study showed a higher event rate compared to those with normal NMR spectroscopy, and similar to the event rate of the women with obstructive CAD.²³ Again, however, the higher event rate was due to hospitalizations for angina and repeat angiography: no deaths or myocardial infarction events were documented in this group.

In summary, the data are simply not there to indicate a major role of coronary endothelial dysfunction and microvascular disease in the etiology and prognosis of ischemic heart disease in women. Even less evidence is available about the role of coronary vessel remodeling. It is not that these hypotheses are incorrect; it is mainly that research has been too limited. We do not know how prevalent these conditions are among women who have ischemic heart disease or are at risk for the disease. We do not know if these mechanisms are more prevalent in women than in men, which would help explain sex differences in presentation and outcome of ischemic heart disease. Finally, we do not know if they are associated with adverse events such as acute myocardial infarction or death. Presently, we are far from being able to conclude, or even suggest, that these hypothesized abnormalities play a larger etiologic or prognostic role for ischemic heart disease among women than among men.

Do Women Fare Worse than Men after Acute Coronary Syndromes?

A general pattern of higher mortality and complication rates in women after acute coronary syndromes (ACS) compared with men has been described for many years. But what should be recognized is that sex differences in mortality after ACS do not occur across the board, but only in specific patient subgroups. The first is the ST-segment elevation MI (STEMI) patients.^{4, 24, 25} In contrast to these STEMI patients, no sex differences are usually found among the non-ST segment elevation MI (NSTEMI) patients after adjustment for risk factors, and among unstable angina patients; women actually do significantly better than men after correction for age and risk factors.^{4, 24} The second group in which sex differences in outcome are found are the younger MI patients, as reported by many population-based and registry studies.^{9, 24, 26–30} Among older patients, there are no differences or even a tendency for women to do better. This effect modification due to age is less apparent in datasets from randomized clinical trials,^{4, 31} probably due to the selection characteristics and possible differential enrollment by sex in these trials.

Little is known about why women face higher risks than men in these patient groups. Differences by MI type may be due to the pathophysiology underlying these events. For example, acute occlusion due to thrombus superimposed on a ruptured or eroded atherosclerotic plaque is believed to play a larger role in transmural infarctions than other types of ACS.³² Thus, it is possible that sex differences in vessel size and collateralization put women at greater risk than men after STEMI but not after other types of ACS.

It is also unclear why sex differences in the outcome of MI are seen in young and middle-aged patients but not older patients. One would expect that women less than 50 years of age, the majority of whom are premenopausal, should be more advantaged, rather than less advantaged, compared with men of similar age in terms of survival. On the other hand, in

order for coronary disease to occur in younger women, it must be aggressive, or driven by multiple risk factors, or due to secondary or unknown causes. That is, the delayed onset of coronary disease in women could in part drive sex difference in risk profile on presentation and paradoxically also drive their poorer outcomes. Indeed, younger women with MI compared with men have a higher rate of risk factors and comorbidities such as diabetes, previous history of heart failure, and stroke, although these factors do not entirely explain sex differences in outcome.^{9, 33} It is possible that unaccounted comorbidities and risk factors are responsible for the residual outcome differences seen in comparison with men. Alternatively, other unknown factors may be involved; among these, social and psychological factors have rarely been considered. A recent study, for example, documented a remarkable decrease in mortality in women with coronary heart disease randomized to a stress-reduction intervention specifically tailored to women.³⁴ Although we do not have a full explanation for the excess mortality risk in younger MI women compared with men, this excess risk is narrowing,³³ reflecting a sharper mortality decline among women than men in recent years. This trend suggests that environmental or behavioral causes of sex differences in outcomes may be more important than biological ones.

The declining mortality among post-MI women for cardiovascular mortality is consistent with a decreasing trend in cardiovascular mortality in the entire population of women since the mid-1960's, which is similar to men.³⁵ Yet countless papers have denounced an absence of decline, or even an increase, in cardiovascular mortality among women despite a concurrent decrease in men.^{12, 36–38} These assertions may result from a misinterpretation of mortality statistics that have plotted the number of deaths due to cardiovascular disease.³⁹ The total *number* of deaths (not the death *rate*) due to cardiovascular disease has slightly increased in women, while decreasing in men, until the year 2000. This increase likely reflects the aging United States population and the fact that women live longer than men, since age-standardized rates show a similar decline in women and men over the past several decades in the United States and many other countries in the world.^{35, 40, 41} After the year 2000, in the United States even the *number* of cardiovascular deaths has shown a similar, if not steeper, downward trend in women compared with men.

Are Women with Heart Disease Treated Less Aggressively than Men, and Does Differential Treatment Contribute to Outcome Differences?

A less aggressive clinical management of women with coronary heart disease relative to men has been documented for years, with a tendency to refer to it as sex bias in health care delivery. Most of this literature has been conducted in hospitalized ACS patients. Although it is indisputable that variations in clinical care occur by demographic groups, it should also be recognized that such variations are complex and may be due to a variety of factors other than sex. For example, women with MI are older, have lower levels of biomarkers of cardiac necrosis and have less severe obstructive CAD. Furthermore, in recent studies, reported differences in treatment by sex were small. In the Get With the Guidelines–Coronary Artery Disease (GWTG-CAD) database, differences in receipt of aspirin and beta-blockers between women and men were only 2 percentage points; for example, 93% of the men and 91% of the women received aspirin within 24 hours. Yet such small differences were presented as evidence of treatment disparities.²⁵ Similar results were obtained in other large contemporary databases, including CRUSADE,³⁸ GRACE,⁴² NRMI,⁴³ the CURE trial⁴⁴ and the Medicare database.⁴⁵ The tendency to overstate treatment differences by sex may derive from an excessive reliance on *p* values. As the size of cardiovascular databases available for research continues to grow, we need to be wary that highly significant *p* values may not always denote clinically meaningful differences.

Although sex differences in evidence-based medications are small in almost any recent study, some studies have reported larger differences for reperfusion therapy in STEMI patients, although results vary.^{25, 43, 45} These gaps may in part derive from bleeding concerns among women rather than sex per se. Consistently larger treatment differences are seen for less evidence-based procedures, such as coronary catheterization and revascularization procedures.^{38, 43–45} Even for these interventions, however, it is unclear whether differences reflect true disparities. Women's lower prevalence of obstructive CAD at catheterization explains the lower use of revascularization,^{38, 44} suggesting that, on average, underuse of these procedures in women is not necessarily inappropriate.

Another indication that underuse of treatments and procedures in women with ACS compared with men may not be clinically significant is that it does not seem to account for mortality differences between women and men with ACS, if any are found.^{38, 42, 44, 45} Even in this context there is a tendency to overstate any differences found. In a French MI database, lower use of percutaneous interventions explained less than a half of a percentage point of the mortality difference between women and men; still the authors concluded that one quarter of the gender gap in mortality was related to differential use of PCI.⁴⁶ That conclusion derived from the fact that the age-adjusted difference in mortality was less than 2% in this population.

In a population-based database of MI patients, Alter et al. clearly demonstrated that differences in care have little to no role in explaining sex differences in post-MI mortality.⁴⁷ While care became progressively less aggressive among older women relative to men, survival advantage tracked in the opposite direction, with older women clearly favored. These findings suggest that factors other than treatments should be explored as determinant of survival differences after MI between women and men.

It should be noted that most of the data on sex differences in the clinical management of coronary disease derives from studies of ACS patients. A large knowledge gap involves angina pectoris. Little is known about sex differences in the management of angina, despite its being the most common manifestation of CAD in women and therefore, for many women, representing the starting point for their cardiovascular care delivery. Recent data from Europe suggest that women with angina are less likely to be referred for coronary revascularization and to receive preventive treatments^{48, 49} even after adjusting for clinical factors including presence of perfusion defects.⁴⁸ Older data from the United States suggested similar disparities,^{50–53} but no contemporary data are available to determine whether such differences in referral are still present.

Conclusions

After at least a decade of renewed interest in women's cardiovascular health, we are left with more questions than answers. Fundamental questions about the pathophysiology of ischemic heart disease in women remain unanswered. We have gained few clues about the basis for sex differences in coronary heart disease and what is unique about the female vascular system. As a result, we are yet unable to explain sex differences in the epidemiology, presentation and outcome of coronary heart disease. Key questions remain about why women are protected from cardiovascular disease, why this protection is restricted to the coronary system,⁵⁴ and why this protection ends when women develop diabetes or an acute MI. We lack studies that compare biological mechanisms of disease between women and men, to better define vascular processes that are unique to women. We lack sufficiently large follow-up studies to link such processes to cardiac endpoints. After decades of focusing on estrogen, other pathways should now be considered; among these, are the factors underlying the vascular physiology of pregnancy and menstruation, such as

vascular regeneration and repair, hormonal factors other than estrogen (such as testosterone), autonomic function, and the immune system.

Furthermore, the role of non-biological factors should be evaluated in more detail. Do psychological and behavioral risk factors such as depression, family/work stress, socioeconomic deprivation, and early life adversities, play a larger role in women than in men in increasing their risk for adverse cardiac events? These factors are more prevalent in women but have rarely been evaluated in terms of explaining sex differences in cardiovascular outcomes. Finally, are there true differences in referral rates for diagnostic testing and treatments between women and men with suspected heart disease in the current era, and if so, how can referral rates be increased when appropriate? And how can we increase the inclusion of women in cardiovascular clinical trials? Without an answer to these questions, little can be done to improve the prevention and the treatment of coronary heart disease in women.

Acknowledgments

Funding Sources: Dr. Vaccarino is supported by grant K24 HL077506-06 from the National Institutes of Health.

References

1. Kim ESH, Carrigan TP, Menon V. Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion. *J Am Coll Cardiol* 2008;52:672–673. [PubMed: 18702973]
2. Milner KA, Funk M, Richards S, Wilmes RM, Vaccarino V, Krumholz HM. Gender differences in symptom presentation associated with coronary heart disease. *Am J Cardiol* 1999;84:396–399. [PubMed: 10468075]
3. Vaccarino V, Lin ZQ, Kasl SV, Mattera JA, Roumanis SA, Abramson JL, Krumholz HM. Sex differences in health status after coronary artery bypass surgery. *Circulation* 2003;108:2642–2647. [PubMed: 14597590]
4. Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van der Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mortality following acute coronary syndromes. *JAMA* 2009;302:874–882. [PubMed: 19706861]
5. Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. *Circulation* 2002;105:1176–1181. [PubMed: 11889010]
6. Argulian E, Patel AD, Abramson JL, Kulkarni A, Champney K, Palmer S, Weintraub W, Wenger NK, Vaccarino V. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions. *Am J Cardiol* 2006;98:48–53. [PubMed: 16784919]
7. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. *JAMA* 2005;293:477–484. [PubMed: 15671433]
8. Olson MB, Kelsey SF, Matthews K, Shaw LJ, Sharaf BL, Pohost GM, Cornell CE, McGorray SP, Vido D, Bairey Merz CN. Symptoms, myocardial ischaemia and quality of life in women: results from the NHLBI-sponsored WISE Study. *Eur Heart J* 2003;24:1506–1514. [PubMed: 12919775]
9. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. *N Engl J Med* 1999;341:217–225. [PubMed: 10413733]
10. Pepine CJ, Kerensky RA, Lambert CR, Smith KM, von Mering GO, Sopko G, Bairey Merz CN. Some thoughts on the vasculopathy of women with ischemic heart disease. *J Am Coll Cardiol* 2006;47:S30–S35. [PubMed: 16458168]
11. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Pepine CJ, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, Lerman A, Quyyumi AA, Sopko G. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender

- differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. *J Am Coll Cardiol* 2006;47:S21–S29. [PubMed: 16458167]
12. Shaw LJ, Bugiardini R, Merz CNB. Women and ischemic heart disease: evolving knowledge. *J Am Coll Cardiol* 2009;54:1561–1575. [PubMed: 19833255]
 13. Nicholls SJ, Wolski K, Sipahi I, Schoenhagen P, Crowe T, Kapadia SR, Hazen SL, Tuzcu EM, Nissen SE. Rate of Progression of Coronary Atherosclerotic Plaque in Women. *J Am Coll Cardiol* 2007;49:1546–1551. [PubMed: 17418293]
 14. Han SH, Bae JH, Holmes DR Jr, Lennon RJ, Eeckhout E, Barsness GW, Rihal CS, Lerman A. Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. *Eur Heart J* 2008;29:1359–1369. [PubMed: 18424787]
 15. Kern MJ, Bach RG, Mechem CJ, Caracciolo EA, Aguirre FV, Miller LW, Donohue TJ. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation and coronary artery disease. *J Am Coll Cardiol* 1996;28:1154–1160. [PubMed: 8890809]
 16. Sheifer SE, Canos MR, Weinfurt KP, Arora UK, Mendelsohn FO, Gersh BJ, Weissman NJ. Sex differences in coronary artery size assessed by intravascular ultrasound. *Am Heart J* 2000;139:649–653. [PubMed: 10740147]
 17. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, Lehman BT, Fan S, O'Leary DH, Vita JA. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. *Circulation* 2004;109:613–619. [PubMed: 14769683]
 18. Celermajer D, Sorensen K, Bull C, Robinson J, Deanfield J. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *J Am Coll Cardiol* 1994;24:1468–1474. [PubMed: 7930277]
 19. Juonala M, Kahonen M, Laitinen T, Hutri-Kahonen N, Jokinen E, Taittonen L, Pietikainen M, Helenius H, Viikari JSA, Raitakari OT. Effect of age and sex on carotid intima-media thickness, elasticity and brachial endothelial function in healthy adults: The Cardiovascular Risk in Young Finns Study. *Eur Heart J* 2008;29:1198–1206. [PubMed: 18079136]
 20. Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). *J Am Coll Cardiol* 2006;47:565–572. [PubMed: 16458137]
 21. von Mering GO, Arant CB, Wessel TR, McGorray SP, Bairey Merz CN, Sharaf BL, Smith KM, Olson MB, Johnson BD, Sopko G, Handberg E, Pepine CJ, Kerensky RA. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation* 2004;109:722–725. [PubMed: 14970106]
 22. Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. *N Engl J Med* 2000;342:829–835. [PubMed: 10727587]
 23. Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, Scott KN, Doyle M, Olson MB, Pepine CJ, den Hollander J, Sharaf B, Rogers WJ, Mankad S, Forder JR, Kelsey SF, Pohost GM. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation* 2004;109:2993–2999. [PubMed: 15197152]
 24. Champney KP, Frederick PD, Bueno H, Parashar S, Foody J, Merz CN, Canto JG, Lichtman JH, Vaccarino V. The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarction. *Heart* 2009;95:895–899. [PubMed: 19147625]
 25. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, Wells Q, Bozkurt B, LaBresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E, Wexler L, for the Get With the Guidelines Steering C, Investigators. Sex differences in medical care and early death after acute myocardial infarction. *Circulation* 2008;118:2803–2810. [PubMed: 19064680]
 26. Rosengren A, Spetz CL, Koster M, Hammar N, Alfredsson L, Rosen M. Sex differences in survival after myocardial infarction in Sweden. Data from the Swedish National Acute Myocardial Infarction register. *Eur Heart J* 2001;22:314–322. [PubMed: 11161950]

27. Mahon NG, McKenna CJ, Codd MB, O'Rorke C, McCann HA, Sugrue DD. Gender differences in the management and outcome of acute myocardial infarction in unselected patients in the thrombolytic era. *Am J Cardiol* 2000;85:921–926. [PubMed: 10760327]
28. Kostis JB, Wilson AC, O'Dowd K, Gregory P, Chelton S, Cosgrove NM, Chirala A, Cui T. Sex Differences in the Management and Long-Term Outcome of Acute Myocardial Infarction. *Circulation* 1994;90:1715–1730. [PubMed: 7923655]
29. Andrikopoulos GK, Tzeis SE, Pipilis AG, Richter DJ, Kappos KG, Stefanadis CI, Toutouzas PK, Chimonas ET. Younger age potentiates post myocardial infarction survival disadvantage of women. *Int J Cardiol* 2006;108:320–325. [PubMed: 15963582]
30. Koek HL, de Bruin A, Gast F, Gevers E, Kardaun JWPF, Reitsma JB, Grobbee DE, Bots ML. Short- and long-term prognosis after acute myocardial infarction in men versus women. *Am J Cardiol* 2006;98:993–999. [PubMed: 17027558]
31. Mega JL, Morrow DA, Ostor E, Dorobantu M, Qin J, Antman EM, Braunwald E. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-Elevation myocardial infarction. *Circulation* 2007;115:2822–2828. [PubMed: 17515461]
32. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. *Am J Cardiol* 1995;76:24C–33C.
33. Vaccarino V, Parsons L, Peterson ED, Rogers WJ, Kiefe CI, Canto J. Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. *Arch Intern Med* 2009;169:1767–1774. [PubMed: 19858434]
34. Orth-Gomer K, Schneiderman N, Wang H-X, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in Women with coronary disease: The Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). *Circ Cardiovasc Qual Outcomes* 2009;2:25–32. [PubMed: 20031809]
35. Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. *Heart* 2002;88:119–124. [PubMed: 12117828]
36. Kim ESH, Menon V. Status of women in cardiovascular clinical trials. *Arterioscler Thromb Vasc Biol* 2009;29:279–283. [PubMed: 19221204]
37. Pepine CJ. Ischemic heart disease in women: facts and wishful thinking. *J Am Coll Cardiol* 2004;43:1727–1730. [PubMed: 15145090]
38. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan JGX, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: Large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol* 2005;45:832–837. [PubMed: 15766815]
39. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. for the American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics--2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:e21–e181. [PubMed: 19075105]
40. Rodriguez T, Malvezzi M, Chatenoud L, Bosetti C, Levi F, Negri E, La Vecchia C. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970–2000. *Heart* 2006;92:453–460. [PubMed: 16537758]
41. O'Hara T, Bennett K, O'Flaherty M, Jennings S. Pace of change in coronary heart disease mortality in Finland, Ireland and the United Kingdom from 1985 to 2006. *Eur J Public Health* 2008;18:581–585. [PubMed: 18927185]
42. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA, Eagle KA. Sex-related differences in the presentation, treatment and outcomes among patients with acute

- coronary syndromes: the Global Registry of Acute Coronary Events. *Heart* 2009;95:20–26. [PubMed: 18463200]
43. Vaccarino V, Rathore SS, Wenger NK, Frederick PD, Abramson JL, Barron HV, Manhapra A, Mallik S, Krumholz HM. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. *N Engl J Med* 2005;353:671–682. [PubMed: 16107620]
 44. Anand SS, Xie CC, Mehta S, Franzosi MG, Joyner C, Chrolavicius S, Fox KA, Yusuf S. CURE Investigators. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. *J Am Coll Cardiol* 2005;46:1845–1851. [PubMed: 16286169]
 45. Gan SC, Beaver SK, Houck PM, MacLehose RF, Lawson HW, Chan L. Treatment of acute myocardial infarction and 30-day mortality among women and men. *N Engl J Med* 2000;343:8–15. [PubMed: 10882763]
 46. Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 Nationwide French Hospitals Database. *Circulation* 2007;115:833–839. [PubMed: 17309933]
 47. Alter DA, Naylor CD, Austin PC, Tu JV. Biology or bias: practice patterns and long-term outcomes for men and women with acute myocardial infarction. *J Am Coll Cardiol* 2002;39:1909–1916. [PubMed: 12084587]
 48. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Gender differences in the management and clinical outcome of stable angina. *Circulation* 2006;113:490–498. [PubMed: 16449728]
 49. Murphy NF, Simpson CR, MacIntyre K, McAlister FA, Chalmers J, McMurray JJ. Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. *Heart* 2006;92:1047–1054. [PubMed: 16399851]
 50. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. *Ann Intern Med* 1994;120:559–566. [PubMed: 8116993]
 51. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men. *N Engl J Med* 1991;325:221–225. [PubMed: 2057022]
 52. Steingart RM, Packer M, Hamm P, Coglione ME, Gersh B, Geltman EM, Sollano J, Katz S, Moyer L, Basta LL, Lewis SJ, Gottlieb SS, Bernstein V, McEwan P, Jacobson K, Brown EJ, Kukin ML, Kantrowitz NE, Pfeffer MA. Sex differences in the management of coronary artery disease. *N Engl J Med* 1991;325:226–230. [PubMed: 2057023]
 53. Tobin J, Wassertheil-Smoller S, Wexler JP, Steingart RM, Budner N, Lense L, Wachspress J. Sex bias in considering coronary bypass surgery. *Ann Intern Med* 1987;107:19–25. [PubMed: 3496029]
 54. Kardys I, Vliegthart R, Oudkerk M, Hofman A, Wittteman JC. The female advantage in cardiovascular disease: do vascular beds contribute equally? *Am J Epidemiol* 2007;166:403–412. [PubMed: 17566064]